Unknown PHASE4 INTERVENTIONAL 2-arm NCT05848635

Hydromorphone for Perioperative Analgesia in Lung Tumor Ablation Parallel Controlled

Hydromorphone for Perioperative Analgesia in Lung Tumor Ablation Parallel Controlled ：A Randomized, Parallel Controlled Trial

Sponsor: Qianfoshan Hospital

Conditions Ablation Pulmonary Nodule

Interventions Hydromorphone Hydrochloride Morphine hydrochloride

Updated 4 times since 2023 Last updated: Apr 28, 2023 Started: May 1, 2023 Primary completion: May 1, 2024 Completion: May 1, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Ablation and Pulmonary Nodule and is currently ongoing. Qianfoshan Hospital leads this study, which shows 4 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

May 2025 — Present [monthly]

Unknown PHASE4

Status: Not Yet Recruiting → Unknown
Sep 2024 — May 2025 [monthly]

Not Yet Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE4
Jun 2023 — Jul 2024 [monthly]

Not Yet Recruiting PHASE4

First recorded

May 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Qianfoshan Hospital

Data source: Qianfoshan Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.